181363-06-4

Basic information

• Product Name: Pyrimidine, 4-(bromomethyl)-2-chloro- (9CI)
• Synonyms: Pyrimidine, 4-(bromomethyl)-2-chloro- (9CI);Pyrimidine,4-(bromomethyl)-2-chloro-;4-(Bromomethyl)pyrimidine
• CAS NO: 181363-06-4
• Molecular Formula: C₅H₄BrClN₂
• Molecular Weight: 207.45566
• Product Categories: PYRIMIDINE
• Mol File: 181363-06-4.mol

Chemical Properties

• Boiling Point: 315.3 °C at 760 mmHg
• Flash Point: 144.5 °C
• Appearance: /
• Density: 1.768
• Vapor Pressure: 0.000814mmHg at 25°C
• Refractive Index: 1.597
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Pyrimidine, 4-(bromomethyl)-2-chloro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrimidine, 4-(bromomethyl)-2-chloro- (9CI)(181363-06-4)
• EPA Substance Registry System: Pyrimidine, 4-(bromomethyl)-2-chloro- (9CI)(181363-06-4)

Safety Data

• Hazardous Substances Data: 181363-06-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Pyrimidine, 4-(bromomethyl)-2-chloro(9CI) is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and reactivity contribute to the creation of new and innovative chemical structures with potential biological activity.
Used in Development of New Therapeutic Agents:
Pyrimidine, 4-(bromomethyl)-2-chloro(9CI) is employed in the development of new therapeutic agents, leveraging its unique structure and reactivity to create novel chemical entities with potential applications in medicine.
Used in Organic and Medicinal Chemistry Research:
Pyrimidine, 4-(bromomethyl)-2-chloro(9CI) is utilized in organic and medicinal chemistry research to explore its potential applications and properties, further expanding the understanding of its role in the synthesis of biologically active compounds.
It is important to handle Pyrimidine, 4-(bromomethyl)-2-chloro(9CI) with care, as it may possess hazardous properties.

InChI:InChI=1/C5H4BrClN2/c6-3-4-1-2-8-5(7)9-4/h1-2H,3H2

Upstream product

• 13036-57-2 2-chloro-4-methylpyrimidine 
• 149849-94-5 methyl 2,6-dichloropyrimidine-4-carboxylate 
• 34953-87-2 (2-chloropyrimindin-4-yl)methanol 

Relevant articles and documents

MCL1 INHIBITORS AND USES THEREOF

The present disclosure provides compounds, such as compounds of Formula I, and compositions that are MCL1 inhibitors.

ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE

The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.

Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists

The important roles of the CXCL12/CXCR4 axis in numerous pathogenic pathways involving HIV infection and cancer metastasis make the CXCR4 receptor an attractive target for the development of therapeutic agents. Through scaffold hybridization of a few known CXCR4 antagonists, a series of novel aminopyrimidine derivatives was developed. Compound 3 from this new scaffold demonstrates excellent binding affinity with CXCR4 receptor (IC50 = 54 nM) and inhibits CXCL12 induced cytosolic calcium increase (IC50 = 2.3 nM). Furthermore, compound 3 possesses good physicochemical properties (MW 353, clogP 2.0, PSA 48, pKa 6.7) and exhibits minimal hERG and CYP isozyme (e.g. 3A4, 2D6) inhibition. Collectively, these results strongly support further optimization of this novel scaffold to develop better CXCR4 antagonists.

Enantioselective α-benzylation of aldehydes via photoredox organocatalysis

The first enantioselective aldehyde α-benzylation using electron-deficient aryl and heteroaryl substrates has been accomplished. The productive merger of a chiral imidazolidinone organocatalyst and a commercially available iridium photoredox catalyst in the presence of household fluorescent light directly affords the desired homobenzylic stereogenicity in good to excellent yield and enantioselectivity. The utility of this methodology has been demonstrated via rapid access to an enantioenriched drug target for angiogenesis suppression.